Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BICO, Audiocast with teleconference, Q2'24

By Inderes8/20/2024, 8:00 AM
BICO Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Maria Forss
00:00 - 03:05

Hello and a warm welcome to everyone for joining the BICO AB earnings call for quarter two 2024. My name is Maria Forss and I'm the president and CEO of BICO AB. And together with our CFO Jacob Thordenberg. Today I will present our report. Let's begin with today's agenda. Our agenda today is divided into five sections before the Q&A. We will give a summary of the quarter and highlight significant events. We will also comment on the market developments and thereafter present BICO's financial performance for the quarter, as well as deep dives into the business areas' performance. I will also comment upon the development of our strategic priorities. These sections will be in listening-only mode. After the presentation, we will invite you to our Q&A session where you are welcome to participate. The Financial Hearing host will be back with further instructions. Let's begin with summarizing the quarter. In quarter two, we delivered stable sales levels in line with our peers. Despite a volatile market environment. We delivered sales of 534 million and an organic growth of -2%. Jacob will give you more details on the financials later in this presentation. All business areas were profitable in quarter two, reporting a total adjusted EBITDA for the Group of 46 million, generating a margin of 9%. As mentioned during our earnings call for quarter one, we had some additions to the executive management team as well. Both Katharina Nordland and Anders Gilbane have joined us during the past quarter. Katharina is our chief HR officer and Anders is our chief commercial officer. After the quarter, we have also announced that Andreas Zwicker has been recruited as general counsel. He will succeed Tobias and will be joining us as late as mid-October. Andreas' previous experience and commercial mindset will contribute to further developing our legal function. All in all, we're continuing to build an organization suited for the next phase for BICO. Later in this presentation, I will also comment upon the work done with our strategic priorities and how they have developed since they were launched earlier this year. I will now move on to the second section for today and comment on the market development. This section was introduced last quarter and gives more flavor to the market development, and I will also comment on sales per geography. Indications of a slower business for BICO in the academia and diagnostic segments continued during quarter two 2024, and as you can see on the map, the sales in North America increased, mainly driven by biosciences, whereas Europe was flat, Asia and foremost China experienced a significant drop in sales levels due to lower demand compared to quarter two 2023. I believe that we see the same trends and patterns as many of our peers have reported in quarter two and as mentioned during my previous slide, BICO is performing in line with peers under unpredictable market conditions, and it's time for me to hand over to Jacob for a summary of our financial performance.

Jacob Thordenberg
03:05 - 09:05

Thank you, Maria. And yes, I will now comment on the second quarter of 2024. Please note that all numbers presented are in Swedish kronor. Also, I would like to remind you that from the first quarter of this year, Michael has reported in functional reporting and comparable numbers have been adjusted. Furthermore, all organic growth figures are in constant currency, with sales for the cycle amounting to 534 million and an organic growth of -2%. And I will comment more on sales in the next slide. Adjusted EBITDA amounted to 46 million and EBITDA was 36 million for the quarter, which is an improvement compared to the first quarter of 2024. I also have a separate slide where I will present the EBITDA development during Q2. The gross margin for the quarter amounted to 52%, compared to 46% for the corresponding quarter last year. This can be explained by the product mix and the extraordinary adjustments made in Q2 2023. This is the second quarter we are reporting with the functional reporting structure. The reason why we changed is to increase comparability in the company's cost structure and adapt to the most common market practice. As mentioned also in the Q1 report, this change has affected the reported gross margin negatively as more costs than before have been included. For example, production staff and depreciation of production equipment, etc., have been included in the reported cost of goods sold instead of OpEx. The net loss for the quarter amounted to -79 million. And if we look into sales for the group for the second quarter, the quarter generated sales of 534 million and a flat total sales growth of -0.6% and a negative organic growth of 2% compared with Q2 2023. The second quarter showed mixed sales performance among our companies, following the same pattern as in Q1, where Biosciences showed good sales levels, especially in the lab automation part of our business and a positive organic growth. Bioprinting continued to show weaker sales due to dependency on the academia and research segment, as well as softer sales in Asia and foremost in China compared with Q2 2023. Bioautomation science showed improved sales levels compared with Q1 2024. However, Sana was negatively impacted by dependency on the diagnostics segment, and if we move on to profitability, Adjusted EBITDA for Q2 amounted to 46 million, corresponding to a margin of 9%. EBITDA amounted to 36 million, corresponding to a margin of 7%. All business areas were EBITDA positive in Q2. The improvement compared with the corresponding quarter last year can be explained by lower cost levels, primarily related to personnel. EBITDA trended positively compared with Q1, partially due to seasonality but mainly due to cost-control measures and product mix. As always, staying on course with cost control has been in focus this quarter and will continue to be during the quarters to come. And if we move to the next slide and our cash flow, the cash flow from operating activities for the quarter amounted to -51 million. This includes a negative effect from changes in net working capital of 54 million. Out of this, 20 million was related to increases in operating receivables. Inventories decreased by 32 million, continuing the trend of decreased inventory levels as also seen by the end of last year and which followed in Q1 this year. Cash flow from changes in operating liabilities decreased by 66 million, which was driven by contract liabilities in biosciences converted to revenue, as well as a decrease in accounts payable. Investments in intangible capital expenditures amounted to 6 million. Several R&D projects have been completed in the second half of 2023, with a reduction in capitalized R&D as a result. Investments in tangible CapEx amounted to 15 million, and we didn't pay out any dividends during the quarter, with total estimated remaining earnout payments amounting to 20 million. Total cash flow during Q2 amounted to -101 million, with cash reserves by the end of June amounting to 688 million. Activities to further strengthen cash flow will continue to be a priority for the group. On the next slide, I will further comment on the development of net working capital. This slide shows the development in net working capital between Q2 2023 and Q2 2024. During this period, net working capital has decreased from 527 million to 519 million and has been stable around a level of 20 to 25%. Thus, to conclude, we have shown that the actions implemented in 2023 to improve working capital were successful and resulted in our company now having levels of net working capital in line with industry peers. Maria Forss will now comment on our three business areas. Performance in these areas is as follows:

Maria Forss
09:06 - 13:47

Thank you. I will guide you through our business areas' performance for the second quarter, starting with bioprinting. That area reported net sales of 156 million in quarter two. The organic growth in the segment was -12%, and the adjusted EBITDA was 23 million, corresponding to a margin of 15%. Bioprinting generated weaker sales of -12% compared to the corresponding quarter last year. And this can be explained by a softer market, primarily for the instrument-oriented companies within the bioprinting business area. Adjusted EBITDA was in line with the corresponding quarter last year, with a margin of 15%, and trended positively compared to quarter one due to continued cost control. Moving on to Biosciences. In quarter two, the business area's net sales amounted to 280 million. The organic growth was 7%, and the adjusted EBITDA was 23 million, corresponding to a margin of 8%. The business area showed stable sales levels in the quarter compared with the corresponding quarter last year, as well as an organic growth of 7%. The growth in sales for the quarter and the general cost consciousness generated an adjusted EBITDA margin of 8%. The Bioautomation business area reported net sales of 99 million in quarter two. The organic growth for the quarter was -6%, and adjusted EBITDA amounted to 18 million, corresponding to a margin of 18%. Bioautomation, organic sales growth was -6% compared to the corresponding quarter last year and still hampered by continued weak demand from the diagnostics industry. The Bioautomation business area showed improved sales levels compared to quarter one and delivered an adjusted EBITDA margin of 18% thanks to improved sales during the quarter and cost-cutting measures. Before we move into the Q&A, I would like to comment on the development of our strategic priorities. These were launched earlier this year shortly after I joined BICO AB, and we have worked with them to maintain momentum while executing the updated strategy. So, if we move on to the next slide, I will give you a brief update about the developments in the strategic areas. If we start with the first area, driving commercial excellence, this has been strengthened by the recruitment of our Chief Commercial Officer, Andrew Gilby, who joined us in June this year. He has taken the lead on strengthening commercial excellence as well as several group commercial initiatives such as ensuring collaboration both within the group as well as with external parties. And I'm very much looking forward to seeing the results of Andrew's work. This will be a key area also in our updated strategy for strategic review. I provided an update in the first-quarter report about the extensive review being made of our R&D roadmap and also product portfolio. This has provided us with additional insights about what to focus on and also how we should scale our business lines. We have also invested more in people and culture, and Kate Nolan, our Chief HR Officer, joined us in April during the second quarter. She has set up a global HR organization to implement that, as well as putting in an HR strategy. Um, and these are important cornerstones when building a people-centric and high-performance culture. In addition, strategic recruitment and appointments have been made in our operating companies during the quarter. Last but not least, we have continued to work with initiatives related to operational excellence for a sound cost structure and increased efficiency. Here I worked with a preferred supplier portfolio, consolidated the number of suppliers, and standardized our agreements with them, as well as lowering our inventory levels, to mention some examples. All in all, these four areas are paving the way for the updated strategy for BICO 2.0, which will be presented during our Capital Markets Day on September 17th. In addition, a deep dive into lab automation will be presented during the Capital Markets Day, and you can choose to either participate by attending physically at BICO's head office in Gothenburg or digitally. And if you intend to participate in Gothenburg, please send an email to us at bico@bico.com no later than September 12th, and for digital participation please visit bico.com or use the QR code that you see on the screen. We look forward to welcoming you. Now it's time for the Q&A. Please follow the instructions from the financial hearing host.

Operator
13:51 - 14:15

If you wish to ask a question, please press Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please press Pound Key six on your telephone keypad. The next question comes from Richard Krantz from Handelsbanken. Please go ahead.

Richard Krantz
14:17 - 15:05

Good morning and thank you for taking my questions. So, starting off, maybe you could comment a little bit on the trends you were picking up in the quarter. As you know, we've come quite far into Q3, and maybe comment a little bit on the trends you're seeing in underlying investment appetite for CapEx, for instrumentation or general customer activity. I know in Q1 you pointed out some positive signals in North America and Europe. Um, so maybe you could comment a little bit on the trends and direction of demand and customer activity. Um, here. Thank you.

Maria Forss
15:07 - 16:30

Thank you for that question. Um, as we saw, the second quarter continued the trends we saw in the first quarter. And that is also what we see moving forward. Um, when it comes to trends in the market, we can see that there is still some hesitancy in capital equipment investments, especially in academia, as well as the diagnostic sector, while companies that are more focused on consumables or lab automation are paving the way differently. And that's in line with what we also see that our peers are reporting. So when it comes to the different geographies, I would say that since we have sales in 65 countries and also our presence in so many different segments, we are not as dependent on China as others might be. However, there is still a slow market in Asia, especially China, where some of the structural support expected from the Chinese government has not yet shown results. But sales for Europe and North America are strong as, we are present in both of these markets. So, there's nothing different to compare between quarter one and quarter two. Jacob, do you want to add anything?

Jacob Thordenberg
16:31 - 16:32

I think that's a fair summary.

Richard Krantz
16:35 - 16:53

All right. But to put a finer point on it, do you expect to deliver organic growth above the sort of 1% level we've seen in the first half as we move into the second half? Or do you see momentum remaining similar to what we've seen in H1 in the second half?

Jacob Thordenberg
16:54 - 17:02

Well, Richard, as you know, we don't provide any financial guidance. So, it's very difficult to comment on that without providing financial guidance.

Richard Krantz
17:04 - 17:25

Okay. And just a question on selling and science. Can you confirm that these subsidiaries had a negative impact on both growth and earnings in the quarter? And when do you expect we should start seeing a positive earnings contribution from these two subsidiaries?

Jacob Thordenberg
17:26 - 17:50

Yes, that again goes into giving specific financial guidance for specific operating companies within BICO AB. But I can confirm that they were both loss-making in the quarter and loss-making in the first half of 2024. However, we will not provide any guidance as to when or in what amounts we can expect in terms of profitability.

Richard Krantz
17:53 - 18:26

Okay. And a final question on the cash flow. So even though there's some positive development on inventory, there's still quite negative net working capital development here, weighing on the cash flow. So maybe you could elaborate a bit more on the moving parts and when we should start to expect significant improvements in free cash flow on the positive side of things.

Jacob Thordenberg
18:27 - 19:33

Yes. So it's two questions in one, right? It's the cash flow from the business and the cash flow from working capital. And let me start with the cash flow from the business. As you know, we have full focus on delivering on all the strategic priorities that Maria mentioned, including sales and executing all measures within our operational excellence program to strengthen profitability. So that's something that we are doing which is related to human resources. But then when it comes to working capital, as I mentioned also in the presentation, we have now reached stable levels in our working capital of around 20-25%. However, in our biosciences segment, especially related to lab automation, which is a project-based business, there is a dynamic where working capital, to some extent, jumps up and down when we finish or start larger projects. But all in all, we are very satisfied with the development in that working capital.

Richard Krantz
19:37 - 19:42

All right. So I guess then we should expect continued improvements on that front in the coming quarters.

Jacob Thordenberg
19:43 - 20:09

Not material, not the way that we have seen from the very high levels in 2023 to now, the levels of around 20-25%. So the major improvements in working capital were made at the end of 2023 and onwards. Of course, we continue to work with working capital and strive to improve it further. But most of the improvements have now been implemented, and we are now at acceptable levels of working capital.

Richard Krantz
20:11 - 20:12

Okay.

Jacob Thordenberg
20:13 - 20:14

All right.

Operator
20:19 - 20:24

The next question comes from Ulrich Ratner from Carnegie. Good morning, everyone.

Ulrich Ratner
20:27 - 21:22

Thank you very much. And a few questions on my end. This is the first quarter in company history where all segments report a positive EBITDA contribution to the group. Can you discuss the cost savings achieved over the last year, along with additional savings for Cyanogen, and before selling? Additionally, can you help us understand the improvements in margins compared to Q1? Is it purely volume or additional cost savings? And you didn't hear in the report that we should expect more financial impacts in the second half of the year? And if you can help us, please give us some direction on what that should entail. Um, for the second half of the year, that would be my first question, please.

Unknown
21:22 - 21:23

Um.

Jacob Thordenberg
21:23 - 22:07

As I said to Erica, we don't give any financial guidance, but I can, of course, talk a little bit about the dynamics in our business. So, Q3 and Q4 are by far the seasonally strongest quarters in terms of top-line, hence the savings that we have now implemented in signing Union and Sedlak, and also in other group companies. The results from these savings will be more transparent as we see the topline increasing in Q3 and Q4, provided we follow the usual seasonal pattern.

Ulrich Ratner
22:11 - 22:31

Is it possible to give some indication of how many companies currently in the group are loss making? We can do it by using a rolling 12-month period, or alternatively, if you're able to provide the type of information currently requested.

Jacob Thordenberg
22:31 - 22:47

We will not provide that type of information. Of course, we have previously mentioned Cyanogen and Selling as companies where we have faced profitability issues, but we won't delve into more details than that.

Ulrich Ratner
22:49 - 23:02

And I guess you would not provide the operating margins of the top-tier companies within the group? I know we previously discussed that business operating above 20%, but we won't.

Jacob Thordenberg
23:03 - 23:04

We won't provide those details.

Ulrich Ratner
23:06 - 23:49

Um, the next question would be on the Biosciences segment. Um, and which obviously includes bioconvergence. And there is some volatility, if we were to call it that, between quarters and in both organic growth as well as on the margin side. And I guess that mainly relates to the project-based business, which would have been bioautomation or is bioautomation. Are there any significant deliveries expected in the second half of the year? Was Q2 a normalized quarter? Just for clarity, were there any exceptional deliveries in Q1 of this year?

Jacob Thordenberg
23:51 - 24:29

Yes, as mentioned in the Q1 report, we had an exceptional delivery in Q1 related to a project we won at the end of last year, which was worth $28 million. That was the impact we observed in Q1 within our lab automation business. In Q2, we did not see the same positive impact from any large project. However, we anticipate the lab automation business will continue to trend positively. Nevertheless, it may not align with the results we saw in Q1.

Ulrich Ratner
24:30 - 24:54

Regarding general market demand, considering our strong position in the life science tools industry and our specialized lab automation solutions, do you see diverging trends compared to the muted developments reported by our peers?

Maria Forss
24:56 - 26:08

As a leading provider in lab automation with our Biocon software featuring the 'green button go' for orchestrating lab workflows with biosphere, we address the necessary cost efficiencies and improvements in the life sciences, particularly for pharmaceutical companies. With biosphere, we offer a solution to some of the challenges faced by life science firms. Indeed, we are positively distinguishing ourselves in a market that is overall facing negative trends. To clarify, there is inherent volatility due to the project-based nature of our business, which will continue to be evident as large projects are won. This results in financial influxes during specific quarters followed by continuous operation. Project acceptance tests and SATs influence subsequent revenue generation phases. The lumpiness of project business is typical and does not reflect the overall health of the business.

Ulrich Ratner
26:09 - 27:04

Okay, great. And my last question builds on Richard's earlier inquiries about cash flow. Operational cash flow appears to be flat year-over-year. No, there's a significant improvement; CapEx is down quite substantially. We are now facing a net debt of slightly above $700 million. How reassured are you about refinancing your convertible debt? I assume the timing for this would be around 2025? Additionally, I couldn't find any comments on factoring used in Q2. Could you see factoring as a method to reduce your leverage from current levels?

Jacob Thordenberg
27:05 - 27:56

Let me comment on that. Regarding the convertible bond, we are, as you know, heavily focused on delivering all our strategic priorities, including enhancing the top line and improving profitability. More details about our updated strategy will be discussed at our upcoming Capital Markets Day. To address your question, we are very confident that we will successfully refinance the convertible bond. Regarding your second question about factoring. We haven't used entering, uh, any more levels of factoring in the quarter. And we are, of course, into all options to find sources to refinance the convertible, Including sort of credit facilities, etc.. Related to working capital?

Ulrich Ratner
27:57 - 28:05

Yeah. Yeah, that's that's perfect. Thank you very much. That was all questions on my end and I'll get back into the queue. Thank you.

Maria Forss
28:05 - 28:06

Thank you Ricky.

Operator
28:12 - 28:17

The next question comes from Holger Eckhoff from private. Please go ahead.

Unknown 2
28:20 - 28:37

Hey, uh, thank you, Jakob and Maria for the presentation. I was just curious that beside all the ongoing work that we are doing on kind of cost savings, if there's any activities of divestments of the companies which are not performing right now.

Jacob Thordenberg
28:38 - 28:44

There are no decisions on divesting any or any of the companies within the group.

Unknown 2
28:47 - 29:06

So you will continue to, uh, kind of restructure the companies. And can we expect as a part of the ongoing work, there might be a new structuring that, you know, companies like Sinon and Biosphere will interact more in the future.

Unknown
29:08 - 29:10

That's that's definitely.

Jacob Thordenberg
29:10 - 29:22

Potential part of the future and something that we will address even further in our upcoming Capital Markets Day, where we will talk about, uh, the by code 2.0 and our updated strategy.

Unknown 1
29:24 - 29:25

All right.

Maria Forss
29:25 - 29:55

I might add to that as well, given that, uh, when our integrating, uh, some of the things that were not possible to be done during the pandemic, um, there is a very positive momentum in terms of the opportunities and collaboration spirit between the companies where we have, together with our new CEO, Anders Ford, identified both internal collaboration opportunities as well as external collaboration opportunities, and that will continue also moving forward.

Unknown 2
29:58 - 29:59

Very good. Thank you very much.

Maria Forss
30:00 - 30:01

Thank you.

Unknown
30:01 - 30:02

All right. Thanks a lot. Again.

Operator
30:05 - 30:36

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Maria Forss
30:39 - 30:49

Thank you, everyone, for joining our earnings call. And thank you for all the questions. And together with Jakub, I would like you to wish everyone a great Tuesday. Thank you and goodbye.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…